Prometheus Biosciences In... (RXDX)
NASDAQ: RXDX
· Real-Time Price · USD
199.92
0.18 (0.09%)
At close: Jun 15, 2023, 8:00 PM
0.09% (1D)
| Bid | n/a |
| Market Cap | 9.56B |
| Revenue (ttm) | 4M |
| Net Income (ttm) | -149.13M |
| EPS (ttm) | -3.54 |
| PE Ratio (ttm) | -56.47457627118644 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 1,787,021 |
| Avg. Volume (20D) | 1,217,911 |
| Open | 199.68 |
| Previous Close | 199.74 |
| Day's Range | 199.92 - 199.96 |
| 52-Week Range | 23.27 - 199.96 |
| Beta | -0.49 |
About RXDX
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated ...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 12, 2021
Employees 97
Stock Exchange NASDAQ
Ticker Symbol RXDX